REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Biological: RC18 240 mgBiological: RC18 160 mgBiological: Placebo
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04078386
- Locations
- 🇨🇳
Remegen,Ltd., Yantai, Shandong, China
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04073602
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03809013
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: RC28-E
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03777254
- Locations
- 🇨🇳
Beijing Tongren Hospital .Cmu, Beijing, China
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
- Conditions
- HER2 Overexpressing Gastric CarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 127
- Registration Number
- NCT03556345
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT03507166
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, N/A = Not Applicable, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, N/A = Not Applicable, China
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Conditions
- Breast NeoplasmsBreast DiseasesCapecitabineHER2-positive Breast CancerHER2 Positive Breast CarcinomaHER2-positive Advanced Breast With Liver Metastases
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT03500380
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
- Conditions
- Neuromyelitis Optica Spectrum Disorders
- Interventions
- Biological: PlaceboBiological: RC18 160 mg
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT03330418
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: RC48-ADC 2.5 mg/kg (HER2 Positive)Drug: RC48-ADC 1.5 mg/kg (HER2 Positive)Drug: RC48-ADC 2.0 mg/kg (HER2 Positive)Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT03052634
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The first bethune hospital of jilin unversity, Changchun, Jilin, China
🇨🇳Liaoning cancer hospital & institute, Shenyang, Liaoning, China
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
- Conditions
- Moderate and Severe RheumatoId Arthritis
- Interventions
- Biological: Placebo plus MTXBiological: RC18 160 mg plus MTX
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT03016013
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China